Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.

Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription (STAT) 5 plays a role in tumour prog...

Full description

Bibliographic Details
Main Authors: Holger H H Erb, Julia Bodenbender, Florian Handle, Tamara Diehl, Lukas Donix, Igor Tsaur, Martin Gleave, Axel Haferkamp, Johannes Huber, Susanne Fuessel, Eva Juengel, Zoran Culig, Christian Thomas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0237248

Internet

https://doi.org/10.1371/journal.pone.0237248

Similar Items